Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Erbitux Hearing Suggests Need To Revisit Fast Track Process – Rep. Burr

Executive Summary

The Erbitux development problems suggest that the Fast Track process may not be working as well as expected, Rep. Richard Burr (R-N.C.) said during a June 13 Energy & Commerce/Oversight Subcommittee hearing on the ImClone/Bristol oncologic agent

You may also be interested in...



FDA Oncology Reviews Need Common “Best Practices” – Erbitux Follow-Up

FDA's drug and biologic centers should institute common "best practices" for oncology reviews, the Energy & Commerce Committee told the agency in a June 27 follow-up to the Erbitux hearing

FDA Oncology Reviews Need Common “Best Practices” – Erbitux Follow-Up

FDA's drug and biologic centers should institute common "best practices" for oncology reviews, the Energy & Commerce Committee told the agency in a June 27 follow-up to the Erbitux hearing

Clinical Trial Oversight May Be Ongoing Theme After Erbitux Hearing

The "lack of discipline" among clinical trial investigators involved in colorectal cancer studies of ImClone/Bristol's Erbitux may suggest a need for congressional action, Rep. Ernie Fletcher (R-Ky.) said

Related Content

UsernamePublicRestriction

Register

PS040041

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel